论文部分内容阅读
目的探讨莫西沙星治疗老年社区获得性肺炎的临床疗效。方法 100例患者,将其分为对照组(50例)与观察组(50例),两组患者的疗程均为10 d,对照组给予1次/d静脉连续点滴左氧氟沙星(400 mg),观察组给予1次/d静脉连续点滴莫西沙星注射液(400 mg),患者症状明显改善后改为1次/d口服莫西沙星片(400 mg)。观察莫西沙星治疗老年社区获得性肺炎的临床疗效。结果观察组的临床疗效明显高于对照组,差异有统计学意义(χ2=8.21,P<0.05)。观察组的细菌疗效明显高于对照组,差异有统计学意义(χ2=7.18,P<0.05)。两组患者均有患者出现,两组间副反应发生率差异无统计学意义(P>0.05)。副反应均较轻,患者可耐受,不影响治疗,经对症处理后缓解。结论莫西沙星治疗老年社区获得性肺炎疗效显著,值得临床推广应用。
Objective To investigate the clinical efficacy of moxifloxacin in the treatment of elderly community-acquired pneumonia. Methods 100 patients were divided into control group (50 cases) and observation group (50 cases). The course of treatment in both groups was 10 days. The control group was given intravenous levofloxacin (400 mg) Patients were treated with moxifloxacin (400 mg) intravenously once a day, and moxifloxacin (400 mg) orally once daily after the symptoms were improved. To observe the clinical efficacy of moxifloxacin in the treatment of elderly community-acquired pneumonia. Results The clinical efficacy of the observation group was significantly higher than that of the control group, the difference was statistically significant (χ2 = 8.21, P <0.05). The efficacy of bacteria in the observation group was significantly higher than that in the control group (χ2 = 7.18, P <0.05). There were patients in both groups, with no significant difference in the incidence of side effects between the two groups (P> 0.05). Side effects are mild, patients can be tolerated, does not affect the treatment, symptomatic relief after treatment. Conclusion Moxifloxacin treatment of elderly community-acquired pneumonia is significant and worthy of clinical application.